Table 3.
Responsiveness (LTPR) to clopidogrel in patients treated without and with PPIs.
| Addictive Models | |||||||
| Criteria in Defining LTPR | Group 1 Responders for Treated without PPI | Group 2 Responders for Treated with PPI | P value | Crude AR Difference (95% CI) | P value | Adjusted AR Difference (95% CI)† | P value |
| (1) By inhibition >20% | |||||||
| Any PPIs | 63/122 (51.6%) | 41/90 (45.6%) | .3811 | 6.1% (−7.5–19.7%) | 0.3800 | 3.5% (−10.7–17.7%) | .6297 |
| Individual PPI | |||||||
| Lansoprazole | 63/122 (51.6%) | 23/44 (52.3%) | .9425 | −0.6% (−17.9– 16.6%) | 0.9425 | −3.0% (−20.6–14.7%) | .7406 |
| Dexlansoprazole | 63/122 (51.6%) | 6/24 (25.0%) | .0169∗ | 26.6% (7.2–46.1%) | 0.0073∗ | 10.5% (2.6–43.6%) | .0274∗ |
| Pantoprazole | 63/122 (51.6%) | 7/16 (43.8%) | .5529 | 7.9% (−18.0–33.8%) | 0.5501 | 5.6% (−20.5–31.8%) | .6722 |
| Esomeprazole | 63/122 (51.6%) | 8/17 (47.1%) | .7134 | 11.6% (−14.7–38.0%) | 0.3863 | 9.4% (−17.2–36.0%) | .4871 |
| Rabeprazole | 63/122 (51.6%) | 6/8 (75.0%) | .2004 | −23.4% (−54.7–7.9%) | 0.1434 | −26.9% (−58.9–5.1%) | .0991 |
| (2) By PRU <235 | |||||||
| Any PPIs | 82/122 (67.2%) | 53/90 (58.9%) | .2129 | 8.3% (−4.8– 21.5%) | 0.2145 | 4.1% (−9.8–17.9%) | .5657 |
| Individual PPI | |||||||
| Lansoprazole | 82/122 (67.2%) | 27/44 (61.4%) | .4836 | 5.9% (−10.8–22.5%) | 0.4904 | 1.9% (−15.2– 19.0%) | .8274 |
| Dexlansoprazole | 82/122 (67.2%) | 12/24 (50.0%) | .1075 | 17.2% (−4.5–38.9%) | 0.1195 | 12.0% (−10.7–34.7%) | .2989 |
| Pantoprazole | 82/122 (67.2%) | 8/16 (50.0%) | .1741 | 17.2% (−8.7–43.1%) | 0.1923 | 14.2% (−11.7– 40.0%) | .2830 |
| Esomeprazole | 82/122 (67.2%) | 8/15 (53.3%) | .2853 | 13.9% (−12.7– 40.5%) | 0.3062 | 9.4% (−18.5– 37.3%) | .5091 |
| Rabeprazole | 82/122 (67.2%) | 7/8 (87.5%) | .2316 | −20.3% (−44.7–4.1%) | 0.1030 | −25.5% (−50.8–0.2%) | .0484∗ |
| (3) By PRU <262 | |||||||
| Any PPIs | 89/122 (73.0%) | 59/90 (65.6%) | .2463 | 7.4% (−5.2–20.0%) | 0.2496 | 3.1% (−9.6–15.9%) | .6296 |
| Individual PPI | |||||||
| Lansoprazole | 89/122 (73.0%) | 31/44 (66.7%) | .7511 | 2.5% (−13.1–18.1%) | 0.7541 | −1.1% (−16.3–14.0%) | .8843 |
| Dexlansoprazole | 89/122 (73.0%) | 12/24 (50.0%) | .0260∗ | 23.0% (1.5–44.5%) | 0.0364∗ | 15.8% (−6.8–38.4%) | .1695 |
| Pantoprazole | 89/122 (73.0%) | 10/16 (62.5%) | .3827 | 10.5% (−14.6–35.5%) | 0.4125 | 7.8% (−16.0– 31.6%) | .5201 |
| Esomeprazole | 89/122 (73.0%) | 9/15 (60.0%) | .2942 | 13.0% (−13.1–39.0%) | 0.3292 | 6.7% (−20.9–34.1%) | .6384 |
| Rabeprazole | 89/122 (73.0%) | 7/8 (87.5%) | .3643 | −14.6% (−38.8–9.7%) | 0.2393 | −21.7% (−46.9–3.5%) | .0917 |
AR = absolute risk, LTPR = low on-treatment platelet reactivity, PPI = proton pump inhibitor.
∗
Statistical significance (P <.05).
†
Model was adjusted with covariate of dual antiplatelet use.